» Articles » PMID: 18471514

Virologic and Histologic Features of Chronic Hepatitis B Virus-infected Asymptomatic Patients with Persistently Normal ALT

Overview
Specialty Gastroenterology
Date 2008 May 13
PMID 18471514
Citations 147
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: There is a paucity of data on hepatitis B virus (HBV) DNA levels and histologic lesions in patients with chronic HBV (CHBV) infection and persistently normal alanine aminotransferase (ALT) levels (PNALT). We studied the ALT, HBV DNA levels, and spectrum of histologic lesions in such patients.

Methods: One thousand three hundred eighty-seven incidentally detected asymptomatic hepatitis B surface antigen (HBsAg)-positive patients with >/=1-year follow-up and either PNALT (n = 189; hepatitis B e antigen [HBeAg(+)], 73; HBeAg(-), 116) or persistently or intermittently elevated ALT (PIEALT; n = 1198; HBeAg(+), 530; HBeAg(-), 668) were included.

Results: In the PIEALT and PNALT patients, baseline DNA >/=5-log copies/mL was seen in 73.8% and 60.3% in HBeAg(+) (P = .018) and 76% and 35.3% in HBeAg(-) (P < .001) patients and histologic fibrosis stage >/=2 in 65.5% and 40.2% in HBeAg(+) (P < .001) and 63.9% and 13.8% in HBeAg(-) (P < .001) patients, respectively. Approximately 21% of HBeAg(-) patients with PNALT and HBV DNA <5-log copies/mL had histologically active liver disease (histologic activity index >/=3 and/or fibrosis stage >/=2).

Conclusions: A fair proportion of patients with CHBV infection with PNALT have HBV DNA >/=5-log copies/mL and significant histologic fibrosis. Use of ALT and HBV DNA levels without resorting to liver biopsy to define "inactive carrier state" in HBeAg(-) PNALT patients may miss histologically significant disease in a proportion of patients.

Citing Articles

Expanding treatment indications in chronic hepatitis B: Should we treat all patients?.

Hui R, Mak L, Fung J, Seto W, Yuen M Hepatol Int. 2025; .

PMID: 39961977 DOI: 10.1007/s12072-025-10785-8.


Probability analysis of hepatocellular carcinoma in hepatitis patients in the gray zone.

Zhang J, Yu S, Zhu K, Li S, Huang Y Front Med (Lausanne). 2025; 11():1464981.

PMID: 39776842 PMC: 11703914. DOI: 10.3389/fmed.2024.1464981.


Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea.

Solomon M, Ghebremeskel G, Achila O, Mebrahtu A, Hamida M, Mesfin A Sci Rep. 2025; 15(1):824.

PMID: 39755688 PMC: 11700113. DOI: 10.1038/s41598-024-79600-y.


Determinants of outcomes in patients with hepatitis B virus-decompensated cirrhosis.

Huang Y, Wang J, Chen C, Lee S, Chang C, Liao S Sci Rep. 2025; 15(1):562.

PMID: 39747298 PMC: 11696113. DOI: 10.1038/s41598-024-84413-0.


HBV-Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment.

Tu T, McQuaid T, Jacobson I Liver Int. 2024; 45(1):e16202.

PMID: 39720865 PMC: 11669079. DOI: 10.1111/liv.16202.